Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to next treatment (TTNT) following initiation of OJEMDA exceeded 3.5 years    BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced three-year results from the OJEMDA pivotal Phase 2 FIREFLY-1 trial in an oral presentation at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology.

GlobeNewsWire • Nov 24, 2025

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. EST.

GlobeNewsWire • Nov 18, 2025

Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 161.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Nov 17, 2025

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need and a lack of therapeutic options Day One will apply existing scientific and commercial capabilities to this investigational innovative therapeutic with a clear potential registration path Company to host conference call and webcast today, November 13, 8:00 am Eastern Time BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has signed a definitive merger agreement for Day One to acquire Mersana Therapeutics (“Mersana”).

GlobeNewsWire • Nov 13, 2025

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Day One Biopharmaceuticals (NASDAQ: DAWN) on Thursday agreed to acquire Mersana Therapeutics Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers.

Benzinga • Nov 13, 2025

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval data to also be disclosed for the first time BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) --  Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will present new OJEMDA durability and clinical stability data from the registrational FIREFLY-1 study at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), being held November 19-23, 2025.

GlobeNewsWire • Nov 10, 2025

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript

Day One Biopharmaceuticals, Inc. ( DAWN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Lauren Merendino - Chief Commercial Officer Charles York - COO & CFO Michael Vasconcelles - Head of Research & Development Conference Call Participants Tara Bancroft - TD Cowen, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Ami Fadia - Needham & Company, LLC, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and welcome to Day One Biopharmaceuticals Third Quarter 2025 Financial and Operating Results Conference Call.

Seeking Alpha • Nov 5, 2025

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology on Nov. 23, 2025 Ended the third quarter with $451.6 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, November 4, 4:30 p.m. Eastern Time BRISBANE, Calif.

GlobeNewsWire • Nov 4, 2025

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.38 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 234.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Oct 30, 2025